Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis

Journal of Clinical Microbiology

Volumn 51, Issue 9, 2013, Pages 2964-2969

  Vella, Antonietta ^a   De Carolis, Elena ^a   Vaccaro, Luisa ^a   Posteraro, Patrizia ^b   Perlin, David S ^c   Kostrzewa, Markus ^d   Posteraro, Brunella ^a   Sanguinetti, Maurizio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Ospedale San Carlo   (Italy)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d BRUKER DALTONIK GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; FKS1 GENE; FUNGAL GENE; FUNGUS ISOLATION; FUNGUS MUTANT; GENOTYPE; INCUBATION TIME; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; ECHINOCANDINS; FUNGAL PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS;

EID: 84882755681     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00903-13     Document Type: Article

References (44)

1. Pfaller MA. 2012. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125:S3-S13.
2. Pasqualotto AC, Denning DW. 2008. New and emerging treatments for fungal infections. J. Antimicrob. Chemother. 61:i19-i30.
3. Sucher AJ, Chahine EB, Balcer HE. 2009. Echinocandins: the newest class of antifungals. Ann. Pharmacother. 43:1647-1657.
4. Arendrup MC. 2010. Epidemiology of invasive candidiasis. Curr. Opin. Crit. Care 16:445-452.
5. Marchetti O, Eggimann P, Calandra T. 2010. Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome? Curr. Opin. Crit. Care 16:442-444.
6. Karthaus M, Rüping MJ, Cornely OA, Steinbach A, Groll AH, Lass-Flörl C, Ostermann H, Ruhnke M, Vehreschild JJ. 2011. Current issues in the clinical management of invasive Candida infections-the AGIHO, DMykG,ÖGMM and PEG web-based survey and expert consensus conference 2009. Mycoses 54:e546-e556.
7. Bal AM. 2010. The echinocandins: three useful choices or three too many? Int. J. Antimicrob. Agents 35:13-18.
8. Kanafani ZA, Perfect JR. 2008. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46: 120-128.
9. Castón-Osorio JJ, Rivero A, Torre-Cisneros J. 2008. Epidemiology of invasive fungal infection. Int. J. Antimicrob. Agents 32:S103-S109.
10. Falagas ME, Roussos N, Vardakas KZ. 2010. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int. J. Infect. Dis. 14:e954-e966.
11. Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, McDermott LA, Tsai K, Marty FM, Kontoyiannis DP, Golan Y. 2010. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J. Antimicrob. Chemother. 65:1460-1465.
12. Lass-Flörl C, Perkhofer S, Mayr A. 2010. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 53:1-11.
13. Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846-2856.
14. Alastruey-Izquierdo A, Cuenca-Estrella M. 2012. EUCAST and CLSI: how to assess in vitro susceptibility and clinical resistance. Curr. Fungal Infect. Rep. 6:229-234.
15. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CSLI M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Freiwald A, Sauer S. 2009. Phylogenetic classification and identification of bacteria by mass spectrometry. Nat. Protoc. 4:732-742.
17. Bizzini A, Greub G. 2010. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, a revolution in clinical microbial identification. Clin. Microbiol. Infect. 16:1614-1619.
18. Murray PR. 2010. Matrix-assisted laser desorption ionization time-offlight mass spectrometry: usefulness for taxonomy and epidemiology. Clin. Microbiol. Infect. 16:1626-1630.
19. De Carolis E, Vella A, Florio AR, Posteraro P, Perlin DS, Sanguinetti M, Posteraro B. 2012. Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) for caspofungin susceptibility testing of Candida and Aspergillus species. J. Clin. Microbiol. 50:2479-2483.
20. Arnold RJ, Reilly JP. 1998. Fingerprint matching of E. coli strains with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of whole cells using a modified correlation approach. Rapid Commun. Mass Spectrom. 12:630-636.
21. Marinach C, Alanio A, Palous M, Kwasek S, Fekkar A, Brossas JY, Brun S, Snounou G, Hennequin C, Sanglard D, Datry A, Golmard JL, Mazier D. 2009. MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole. Proteomics 9:4627-4631.
22. Rudensky B, Broide E, Berko N, Wiener-Well Y, Yinnon AM, Raveh D. 2008. Direct fluconazole susceptibility testing of positive Candida blood cultures by flow cytometry. Mycoses 51:200-204.
23. Ingham CJ, Boonstra S, Levels S, de Lange M, Meis JF, Schneeberger PM. 2012. Rapid susceptibility testing and microcolony analysis of Candida spp. cultured and imaged on porous aluminum oxide. PLoS One 7:e33818. doi:10.1371/journal.pone.0033818.
24. De Carolis E, Vella A, Sanguinetti M, Posteraro B. 2012. Abstr. 18th Congr. Int. Soc. Hum. Anim. Mycol., poster P591.
25. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
26. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
27. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
28. Arendrup MC, Kahlmeter G, Rodriguez-Tudela JL, Donnelly JP. 2009. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob. Agents Chemother. 53: 1628-1629.
29. Arendrup MC, Park S, Brown S, Pfaller M, Perlin DS. 2011. Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates. Antimicrob. Agents Chemother. 55:1891-1895.
30. Astvad KM, Perlin DS, Johansen HK, Jensen RH, Arendrup MC. 2013. Evaluation of caspofungin susceptibility testing by the new Vitek 2 ASTYS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common Candida species. Antimicrob. Agents Chemother. 57:177-182.
31. Walker LA, Gow NA, Munro CA. 2010. Fungal echinocandin resistance. Fungal Genet. Biol. 47:117-126.
32. Hoehamer CF, Cummings ED, Hilliard GM, Rogers PD. 2010. Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents. Antimicrob. Agents Chemother. 54: 1655-1664.
33. Havlicek V, Lemr K, Schug KA. 2013. Current trends in microbial diagnostics based on mass spectrometry. Anal. Chem. 85:790-797.
34. Lu JJ, Tsai FJ, Ho CM, Liu YC, Chen CJ. 2012. Peptide biomarker discovery for identification of methicillin-resistant and vancomycinintermediate Staphylococcus aureus strains by MALDI-TOF. Anal. Chem. 84:5685-5692.
35. Wybo I, De Bel A, Soetens O, Echahidi F, Vandoorslaer K, Van Cauwenbergh M, Piérard D. 2011. Differentiation of cfiA-negative and cfiA-positive Bacteroides fragilis isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Clin. Microbiol. 49: 1961-1964.
36. Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskou A, Ramani R. 2012. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagn. Microbiol. Infect. Dis. 73:365-368.
37. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60:613-618.
38. Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B, Soro O, Cauda R, Viscoli C, Tumbarello M. 2007. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn. Microbiol. Infect. Dis. 58:325-331.
39. Perlin DS. 2011. Current perspectives on echinocandin class drugs. Future Microbiol. 6:441-457.
40. Chen SC, Slavin MA, Sorrell TC. 2011. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11-41.
41. Arikan S. 2007. Current status of antifungal susceptibility testing methods. Med. Mycol. 45:569-587.
42. De Carolis E, Posteraro B, Lass-Flörl C, Vella A, Florio AR, Torelli R, Girmenia C, Colozza C, Tortorano AM, Sanguinetti M, Fadda G. 2012. Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-offlight mass spectrometry. Clin. Microbiol. Infect. 18:475-484.
43. Spanu T, Posteraro B, Fiori B, D'Inzeo T, Campoli S, Ruggeri A, Tumbarello M, Canu G, Trecarichi EM, Parisi G, Tronci M, Sanguinetti M, Fadda G. 2012. Direct MALDI-TOF mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J. Clin. Microbiol. 50:176-179.
44. Posteraro B, Vella A, Cogliati M, De Carolis E, Florio AR, Posteraro P, Sanguinetti M, Tortorano AM. 2012. Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based method for discrimination between molecular types of Cryptococcus neoformans and Cryptococcus gattii. J. Clin. Microbiol. 50:2472-2476.